Adamis Pharmaceuticals Provides Update on SYMJEPI Products

SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products through its field sales force. As contemplated by the previously announced termination agreement between Adamis and Sandoz Inc., and the previously announced exclusive distribution and commercialization agreement between Adamis and USWM, USWM has been actively promoting SYMJEPI while preparing to launch through its field sales force. Adamis has also entered into a transition services agreement with Sandoz and USWM, which is intended to minimize any potential impact to patients and customers during the transfer of commercial rights regarding the SYMJEPI products from Sandoz to US WorldMeds.

Dr. Dennis J. Carlo, President and CEO of Adamis, said, “We are very excited that US WorldMeds is now actively promoting both SYMJEPI products. Adamis has always believed that sales reps calling on high-prescribing allergists and primary care physicians was key to the success of SYMJEPI. I am very pleased those efforts are underway and I believe the US WorldMeds commercial infrastructure, combined with their expertise in acquiring and turning around underperforming assets from larger pharmaceuticals companies, bodes well for finally realizing the value of SYMJEPI in the market.”

P. Breckinridge Jones, Sr., CEO of US WorldMeds, added, “We have great expectations for SYMJEPI, and we plan to commit significant sales and marketing resources to leverage our commercial effort. SYMJEPI provides a unique alternative in the established epinephrine market, one which we believe will benefit from our enhanced focus. US WorldMeds is working closely with Sandoz to minimize market disruption while we increase our commercial and distribution efforts. We expect to complete the full transition from Sandoz during the third quarter of 2020.”

About the SYMJEPI Products
SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. In July 2018, Adamis licensed commercial rights for the U.S. to Sandoz Inc. On May 11, 2020, Adamis announced it was reacquiring commercial rights from Sandoz and entering into an exclusive distribution and commercialization agreement with US WorldMeds. Please refer to www.SYMJEPI.com for additional product information.